Abiopharma

New Form DEF 14A - Hilton Worldwide Holdings Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001585689-26-000023 <b>Size:</b> 51 MB

New Form DEF 14A - SiteOne Landscape Supply, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001104659-26-038879 <b>Size:</b> 5 MB

New Form DEF 14A - Motorola Solutions, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001193125-26-139004 <b>Size:</b> 11 MB

New Form ARS - Privia Health Group, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001193125-26-139006 <b>Size:</b> 1 MB

New Form ARS - MERCANTILE BANK CORP <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001042729-26-000001 <b>Size:</b> 3 MB

General Announcement: Dividend Mandate Form - 2025 Second Interim Dividend

New Form DEFA14A - Privia Health Group, Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001193125-26-139002 <b>Size:</b> 72 KB

New Form DEF 14A - MERCANTILE BANK CORP <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001437749-26-010964 <b>Size:</b> 5 MB

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Top Ships Announces Filing of 2025 Annual Report on Form 20-F

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Futu Announces Cash Dividend

New Form DEFA14A - AXIS CAPITAL HOLDINGS LTD <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214816-26-000146 <b>Size:</b> 434 KB